Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
暂无分享,去创建一个
J. Foekens | J. Klijn | M. M. Gelder | E. Diamandis | M. Look | H. Yu
[1] E. Diamandis,et al. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] M. Duffy,et al. The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.
[3] H. Höfler,et al. Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.
[4] E. Diamandis,et al. Prostate-specific antigen in female serum, a potential new marker of androgen excess. , 1997, The Journal of clinical endocrinology and metabolism.
[5] E. Diamandis,et al. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. , 1997, British Journal of Cancer.
[6] E. Diamandis. Prostate specific antigen--new applications in breast and other cancers. , 1996, Anticancer research.
[7] E. Diamandis,et al. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. , 1996, British Journal of Cancer.
[8] P. Lavagnini,et al. Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in breast cancer. , 1996, British Journal of Cancer.
[9] T. Lennard,et al. Prostate‐specific antigen in breast cyst fluid: Possible role of prostate‐specific antigen in hormone‐dependent breast cancer , 1996 .
[10] E. Diamandis,et al. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. , 1996, Clinical chemistry.
[11] M. Duffy,et al. Proteases as prognostic markers in cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] E. Diamandis,et al. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. , 1995, British Journal of Cancer.
[13] D. Katsaros,et al. Prostate-specific antigen in serum of women with breast cancer. , 1995, British Journal of Cancer.
[14] J. Foekens,et al. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. , 1995, Journal of the National Cancer Institute.
[15] P. Sismondi,et al. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. , 1995, Cancer research.
[16] C. Croce,et al. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. , 1995, Cancer research.
[17] E. Diamandis,et al. Prostate‐Specific antigen expression by various tumors , 1995, Journal of clinical laboratory analysis.
[18] S. Hilsenbeck,et al. Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. , 1994, Journal of the National Cancer Institute.
[19] R. Rosato,et al. Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. , 1994, Endocrinology.
[20] J. Foekens,et al. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. , 1994, British Journal of Cancer.
[21] D. Peehl,et al. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. , 1994, The Journal of endocrinology.
[22] T. Laatikainen,et al. Plasma insulin‐like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen , 1994, Cancer.
[23] N. Ling,et al. Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: evidence for stromal epithelial interactions. , 1994, Cancer research.
[24] M. Binoux,et al. In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. , 1994, Journal of Clinical Investigation.
[25] E. Diamandis,et al. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. , 1994, Clinical biochemistry.
[26] M. Papa,et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. , 1993, The Journal of clinical endocrinology and metabolism.
[27] D. Rifkin,et al. Biology and biochemistry of proteinases in tumor invasion. , 1993, Physiological reviews.
[28] J. Foekens,et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.
[29] L. Giudice,et al. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. , 1992, The Journal of clinical endocrinology and metabolism.
[30] P. Lønning,et al. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. , 1992, Cancer research.
[31] W. McGuire,et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] P. Campbell,et al. Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. , 1992, Endocrinology.
[33] J. Oesterling,et al. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.
[34] W. Catalona,et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.
[35] C. Redmond,et al. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. , 1990, Journal of the National Cancer Institute.
[36] K. Ulm,et al. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer , 1990 .
[37] W. Sly,et al. Insulin-like growth factor receptor expression and function in human breast cancer. , 1990, Cancer research.
[38] C. Osborne,et al. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. , 1989, Molecular endocrinology.
[39] J. Foekens,et al. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. , 1989, Cancer research.
[40] J. Farndon,et al. EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTORS ASSOCIATED WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST CANCER , 1989, The Lancet.
[41] M. Duffy,et al. Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.
[42] T. Stamey,et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.
[43] H. Lilja. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. , 1985, The Journal of clinical investigation.
[44] K. Danø,et al. Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.
[45] Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. , 1980, European Journal of Cancer.
[46] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .